Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras
Journal of Medicinal Chemistry · 10.09.2026 · 69 (17) · 20827-20838
DOI: 10.1021/acs.jmedchem.6c01778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.08.2026. Verfasst von Mohan Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou511442, P. R. China. Hauptthemen laut MEDLINE: Lysosomes, Immunoconjugates, Polysaccharides, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Bureau.
Abstract (Originalsprache)
Lysosome-targeting chimeras (LYTACs) induce lysosomal degradation of extracellular and membrane proteins by bridging target proteins with lysosomal trafficking receptors. However, conventional LYTACs often suffer from off-tissue effects, whereas reported tissue-specific LYTACs typically display limited degradation efficiency. To address these challenges, we report a chemically activatable LYTAC platform that leverages tumor microenvironment-specific cues to achieve precise and safe protein degradation in vivo. We designed a glutathione (GSH)-responsive caged mannose-6-phosphate glycan, GSH-pM6P, which was selectively activated within tumor microenvironments characterized by elevated GSH levels. Based on this design, GSH-pM6P was conjugated to an anti-PD-L1 antibody to construct a prodrug-type Pro-LYTAC. In a triple-negative breast cancer mouse model, Pro-LYTAC selectively degraded PD-L1 within tumor tissues, effectively inhibited tumor growth, and markedly reduced hepatic off-target toxicity. Collectively, Pro-LYTAC enabled tumor-specific degradation of target proteins, significantly enhancing the safety and therapeutic window of lysosome-targeted degradation strategies in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou511442, P. R. China.
- School of Chemistry and Materials Science, Nanjing Normal University, Nanjing210046, P. R. China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou510006, P. R. China.
- Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou510006, P. R. China.
ORCID-Profile: Mohan Chen, Qin Fu, Peng Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Bureau
Zitieren
APA
Chen, M., Li, Y., Wei, X., Fu, Q., He, C., Li, Z., Gu, M., Peng, X., & Shi, P. (2026). Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras. Journal of Medicinal Chemistry, 69(17), 20827-20838. https://doi.org/10.1021/acs.jmedchem.6c01778
Vancouver
Chen M, Li Y, Wei X, Fu Q, He C, Li Z, et al. Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras. Journal of Medicinal Chemistry. 2026;69(17):20827-20838. doi:10.1021/acs.jmedchem.6c01778
BibTeX
@article{Chen2026,
author = {Chen, Mohan and Li, Yicun and Wei, Xueting and Fu, Qin and He, Chener and Li, Zheng and Gu, Meina and Peng, Xi and Shi, Peng},
title = {Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {17},
pages = {20827--20838},
doi = {10.1021/acs.jmedchem.6c01778}
}
EUVIMED